Laura M. Periman, MD; and Vance Thompson, MD, FACS
Show Description +
In this year’s first episode of On The Surface, Laura M. Periman, MD, and Vance Thompson, MD, discuss the interconnection between migraine headaches, tear stimulation, trigeminal neuralgia, and dry eye disease (DED). Together, they contemplate the latest developments in neurostimulation and the future of DED treatments.
REFERENCES
Diel RJ, Hwang J, Kroeger ZA, Levitt RC, Sarantopoulos CD, Sered H, Felix ER, Martinez-Barrizonte J, Galor A. Photophobia and sensations of dryness in patients with migraine occur independent of baseline tear volume and improve following botulinum toxin A injections. Br J Ophthalmol. 2019 Aug;103(8):1024-1029. doi: 10.1136/bjophthalmol-2018-312649. Epub 2018 Sep 29. PMID: 30269099; PMCID: PMC6440864.
*Oyster Point Pharma announces positive results in ONSET-2 phase 3 trial of OC-01 nasal spray for the treatment of the signs and symptoms of dry eye disease [press release]. Oyster Point Pharma. May 11, 2020. https://investors.oysterpointrx.com/news-releases/news-release-details/oyster-point-pharma-announces-positive-results-onset-2-phase-3. Accessed February 11, 2021.
Posted: 2/12/2021
Laura M. Periman, MD; and Vance Thompson, MD, FACS
In this year’s first episode of On The Surface, Laura M. Periman, MD, and Vance Thompson, MD, discuss the interconnection between migraine headaches, tear stimulation, trigeminal neuralgia, and dry eye disease (DED). Together, they contemplate the latest developments in neurostimulation and the future of DED treatments.
REFERENCES
Diel RJ, Hwang J, Kroeger ZA, Levitt RC, Sarantopoulos CD, Sered H, Felix ER, Martinez-Barrizonte J, Galor A. Photophobia and sensations of dryness in patients with migraine occur independent of baseline tear volume and improve following botulinum toxin A injections. Br J Ophthalmol. 2019 Aug;103(8):1024-1029. doi: 10.1136/bjophthalmol-2018-312649. Epub 2018 Sep 29. PMID: 30269099; PMCID: PMC6440864.
*Oyster Point Pharma announces positive results in ONSET-2 phase 3 trial of OC-01 nasal spray for the treatment of the signs and symptoms of dry eye disease [press release]. Oyster Point Pharma. May 11, 2020. https://investors.oysterpointrx.com/news-releases/news-release-details/oyster-point-pharma-announces-positive-results-onset-2-phase-3. Accessed February 11, 2021.
Posted: 2/12/2021
Please log in to leave a comment.